| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1021: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | crizotinib (Xalkori®) |
| Formulation | 200 mg and 250 mg hard capsule |
| Reference number | 3207 |
| Indication | Treatment of adults with ROS1-positive advanced non-small cell lung cancer |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/04/2019 |
| NICE guidance | TA1021: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |